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Targeting Apoptosis Defects  
in Cutaneous T-Cell Lymphoma
E. Contassot1 and Lars E. French1
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin’s lymphomas character-
ized by the clonal proliferation of skin-invasive mature T lymphocytes. Because of 
their low proliferative potential, the accumulation of clonal T cells is considered to 
be potentially due to their inability to undergo Fas-mediated apoptosis, a crucial 
process involved in T-cell homeostasis. Several reports have indicated a decrease 
in or absence of Fas expression in tumor cells in significant proportions of CTCL 
patients, whether or not associated with overexpression of apoptosis inhibitors. In 
this issue, Wu et al. confirm the impaired expression of Fas in CTCL cells. Moreover, 
they show that CTCL cells genetically engineered to re-express Fas acquire a sen-
sitivity to FasL-induced apoptosis, opening new avenues for therapeutic interven-
tion strategies in CTCL.
Journal of Investigative Dermatology (2009), 129, 1059–1061. doi:10.1038/jid.2009.14
Mycosis fungoides (MF), the most com-
mon type of cutaneous T-cell lymphoma 
(CTCL), and its leukemic variant, Sézary 
syndrome (SzS), are mature T-cell neo-
plasms characterized by the clonal pro-
liferation of skin-invasive T lymphocytes 
that have the phenotype of mature help-
er T cells. Because of the low replicative 
potential of CTCL cells, it is proposed 
that their accumulation may, to some 
extent, be the result of defective regula-
tion of T-cell apoptosis.
Apoptosis can be triggered by a series 
of stimuli, among which are signals 
transmitted by a family of cell-surface 
receptors—called death receptors—that 
belong to the tumor necrosis factor–
receptor family. Six death receptors are 
known—Fas (CD95, Apo-1), TRAIL-
receptor 1 (DR4), 2 (DR5, Apo-2), tumor 
necrosis factor–receptor 1, TRAMP (DR3, 
WSL-1, Apo-3), and DR6—and all con-
tain a cytoplasmic sequence called the 
“death domain” that couples the death 
receptor to downstream caspases, the 
activation of which leads to apoptosis.
The acquisition of resistance to apop-
tosis as a mechanism involved in tum-
origenesis is well documented. In sev-
eral tumor types, a decrease in or loss 
of cell-surface Fas expression compared 
with that observed in nontumor cells 
of the same lineage has been report-
ed. Likewise, mutations in the DNA 
sequence of death receptors such as Fas, 
DR4, and DR5 have been reported in sev-
eral human cancer types. Furthermore, 
in both mice and humans, Fas gene 
mutations leading to defective Fas/FasL 
signaling have been shown to result in 
lymphoproliferative disorders as a con-
sequence of lymphocyte accumulation 
(Rieux-Laucat et al., 1995). Resistance 
to apoptosis can also occur as a con-
sequence of the aberrant expression of 
intracellular apoptosis inhibitors in tumor 
cells, as reported in many cancer types. 
Among them is the FLICE-inhibitory 
protein (cFLIP), which is an intracellular 
protein that is highly homologous to cas-
pases 8 and 10 and is able to block the 
autoproteolytic cleavage of caspase-8 
that is normally induced upon trigger-
ing Fas-mediated apoptosis. An overex-
pression of cFLIP associated with a high 
expression of Fas has been reported in 
FasL-resistant Hodgkin’s/Reed–Sternberg 
cells, the malignant cells of Hodgkin’s 
lymphoma (Dutton et al., 2004). Similar 
observations have since been reported 
for non-Hodgkin’s lymphoma and sev-
eral other types of cancer. The relevance 
of cFLIP overexpression, and indirectly 
that of death receptor-mediated apop-
tosis in the pathogenesis of lymphoma, 
is supported by mouse models of lym-
phoma engineered to overexpress cFLIP 
in which tumor progression is enhanced 
(Djerbi et al., 1999).
Appropriate Fas-mediated cell death 
is essential in the control of lympho-
cyte homeostasis. Elimination of T cells 
after encountering a specific antigen 
or superantigen normally proceeds via 
activation-induced cell death (AICD), a 
process that is dependent on activation 
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of Fas signaling and subsequent apopto-
sis of the activated T cells. In the absence 
of adequately controlled AICD, T cells 
are likely to accumulate, a situation that 
is observed in vivo in mice and humans 
harboring Fas gene mutations.
In CTCL, tumor cells are hypothesized 
to be mature T cells that accumulate as 
a consequence of defective AICD, and 
defects in Fas-mediated apoptosis have 
been suggested to be a potential cause. 
Decreased expression of Fas on peripher-
al blood CD4+ T lymphocytes in MF and 
SzS was first reported in 2000 (Dereure 
et al., 2000), the same year absent Fas 
expression, as revealed by immunohis-
tochemistry of the tumor cell infiltrates in 
skin biopsies, was shown to be associat-
ed with more aggressive disease (Zoi-Toli 
et al., 2000). Recently, we (Contassot et 
al., 2008) and others (Braun et al., 2007) 
have reported that a decrease, and some-
times a complete loss, of Fas expression is 
a relatively frequent event (25% of cases) 
in lymphocytes from patients with SzS 
(Figure 1, third column). Furthermore, we 
were able to demonstrate that decreased 
expression of Fas was functionally associ-
ated with resistance to Fas-mediated cell 
death. In this issue, Wu et al. confirm this 
observation and highlight a link between 
the transcriptional regulation of Fas and 
sensitivity to FasL-induced apoptosis. 
Indeed, they found weak, if not absent, 
Fas expression by immunohistochemistry 
of skin lesions in 22/23 MF patients and 
2/2 SzS patients. Flow cytometry analysis 
also revealed extremely weak expression 
of Fas in the peripheral blood of 7/7 SzS 
patients when compared with healthy 
donors. Using CTCL cell lines, Wu et al. 
demonstrate that the Fas transcript lev-
els parallel the cell surface expression. 
Interestingly, the authors extend their 
research by demonstrating that the rein-
troduction in three Fas-negative cell lines 
of a normal expression of Fas after trans-
fection of a Fas-containing plasmid (lipo-
fectamine or electroporation) leads to 
significantly enhanced sensitivity (three- 
to fivefold increase in apoptotic cells) for 
FasL-induced apoptosis (Figure 1, first 
column).
Recently, data published by us and 
others revealed that loss of Fas expres-
sion is not the only mechanism by 
which SzS cells become resistant to 
Fas-mediated cell death. In our series 
of patients, 31% of SzS patients had 
T cells that were resistant to FasL, despite 
significant cell-surface Fas expression. In 
these Fas-expressing FasL-resistant SzS 
cell populations, we could demonstrate 
increased expression of the apoptosis 
inhibitor cFLIP (Figure 1, second col-
umn). Similar observations have been 
reported by Braun et al. (2007), suggest-
ing that in CTCL, T cells may acquire 
resistance to Fas-mediated apoptosis 
through at least two independent mech-
anisms, namely loss of cell-surface death 
receptor expression and/or deregulated 
expression of intracellular apoptosis 
modulators such as cFLIP. Although the 
role of other intracellular antiapoptotic 
molecules such as Bcl-2 family members 
has never been functionally investigated 
in CTCL, they have been shown to be 
expressed in CTCL cells and may also 
contribute to resistance to death receptor-
mediated apoptosis (Zhang et al., 2003). 
Interestingly, a recent report shows that 
the in vitro use of a Bcl-2 antagonist 
together with histone deacetylase inhibi-
tors promotes the death of CTCL cells 
(Chen et al., 2008). In this context, it is 
interesting to note that histone deacety-
lase inhibitors have also been shown to 
downregulate cFLIP expression in cancer 
cells (Watanabe et al., 2005).
In summary, recent independently 
conducted studies, including the study 
published in this issue by Wu et al., 
clearly demonstrate that T cells of CTCL 
patients exhibit significant defects 
in apoptosis, notably Fas-mediated 
apoptosis. It is noteworthy that such 
defects are, for unknown reasons, not 
found invariably in CTCL patients, irre-
spective of their tumor burden. Although 
common, loss of Fas expression is not 
universal. Some patients retain normal 
Fas expression and FasL sensitivity, some 
retain normal Fas expression but resist 
FasL-induced apoptosis as a result of the 
overexpression of intracellular inhibi-
tors of apoptosis, and some have lost the 
expression of death receptors. Therefore, 
deregulation of apoptosis in CTCL cells 
is due not only to impaired expression of 
death receptors but also to inappropriate 
expression of the intracellular molecules 
controlling the process. This suggests 
that approaches intended to restore 
death receptor expression, as illus-
trated in this issue by Wu et al., should 
eventually be combined with efforts to 
do wnmodulate apoptosis inhibitory 
Figure 1. mechanisms of apoptosis defects in ctcL and possible therapeutic strategies.  
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molecules such as cFLIP, resulting in 
a therapeutic avenue that benefits the 
majority of patients with CTCL.
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Peroxisome Proliferator-Activating 
Receptors: A New Way  
to Treat Melanoma?
Dirk Schadendorf1
Accumulating evidence suggests that peroxisome proliferator-activated receptor-γ 
(PPARγ)-binding ligands, currently used to treat diabetes, could be used to treat 
melanoma. Dissociation of their effects on apoptosis from pharmacological activity 
(i.e., PPARγ activation) provides a molecular basis for exploiting these compounds 
to develop molecularly targeted anticancer agents. In this issue, Botton and 
co-workers demonstrate in vitro and in vivo antimelanoma effects of ciglitazone, a 
synthetic ligand-activating PPARγ.
Journal of Investigative Research (2009), 129, 1061–1063. doi:10.1038/jid.2009.56
melanoma: a deadly disease
Cutaneous melanoma is the most deadly 
form of skin cancer. Depending on age, 
gender, anatomical site, and tumor thick-
ness, 20–25% of all primary melano-
mas will spread to distant organs. Once 
melanoma has spread to regional lymph 
nodes (stage III disease), 5-year survival 
rates drop to approximately 30–55%. 
Further dissemination to distant visceral 
organs (stage IV disease) is incurable, 
with a median survival time of approxi-
mately 6 to 12 months (Balch et al., 
2001). Progress in the systemic treatment 
of patients with metastatic melanoma has 
been quite limited over the past 25 years. 
Recently, however, several randomized 
clinical trials have laid the groundwork 
for an evidence-based assessment of 
available therapies. (In Germany, the 
anticancer agents dacarbazine, vin-
desine, and cisplatin are registered for 
metastatic melanoma; in other countries, 
fotemustine and the cytokine IL-2 are 
also registered.) The combined conclu-
sion of these randomized trials is that 
there is no survival benefit for patients 
treated with combination chemo(bio)
therapy, contrary to initial expectations. 
Therefore, single-agent approaches 
and treatment under controlled clinical 
trials are now recommended. A pos-
sible exception may be the treatment of 
patients whose significant tumor-related 
symptoms justify the use of more toxic 
poly chemotherapy for palliative reasons.
Although various agents with novel 
modes of action—including CTLA4 anti-
bodies, signal transduction inhibitors, 
and reactive oxygen species–inducing 
agents such as elesclomol—are being 
tested in clinical phase III registration 
trials worldwide, alternative and more 
effective treatment approaches are need-
ed to improve the outcome for these 
patients. However, the route from target 
identification to an anticancer molecule 
suitable for complete pharmaceutical 
development is long, cumbersome, and 
expensive. Therefore, drugs already reg-
istered for the treatment of one disease 
but potentially effective for melanoma 
cells are of high interest.
PPars in dermatology
Peroxisome proliferator-activated receptors 
(PPARs) are ligand-activated transcription 
factors of the nuclear hormone receptor 
superfamily, comprising three subtypes: 
PPARα, PPARγ, and PPARδ/β. Activation 
of PPARα reduces triglycerides and aids 
in the regulation of energy homeostasis. 
Activation of PPARγ causes insulin sen-
sitization and enhances glucose metabo-
lism, and activation of PPARδ enhances 
fatty acid metabolism.
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